MANNINO RAPHAEL J 4
4 · Matinas BioPharma Holdings, Inc. · Filed Jun 24, 2021
Insider Transaction Report
Form 4
MANNINO RAPHAEL J
Chief Scientific Officer
Transactions
- Other
Common Stock, par value $0.0001 per share
[F1]2021-06-19+8,000→ 1,437,565 total - Conversion
Common Stock, par value $0.0001 per share
[F2]2021-06-19+20,000→ 1,457,565 total - Conversion
Series B Preferred Stock
[F2]2021-06-19−10→ 0 totalExercise: $0.50From: 2018-06-21→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
- [F2]On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.
Signature
/s/ Keith A. Kucinski, attorney-in fact for Raphael J. Mannino|2021-06-24